University Of Liverpool

University Of Liverpool, a UK-based non-profit research institution, performs federal research and development contracts and serves as a prime recipient on federal grant programs and as a sub-recipient on multi-institutional research grants, with balanced split between prime (51% of recent awards) and sub work (49%). The university operates without federal contract vehicles and does not hold set-aside designations.

University Of Liverpool's prime contract work concentrates in biotechnology research and infectious-disease characterization. Recent definitive contracts include a $350 thousand engagement with the Food and Drug Administration awarded August 2026 for sequencing and genomic characterization of Bundibugyo virus from up to 1,000 clinical samples collected during an outbreak in the Democratic Republic of Congo and Uganda, using Illumina NovaSeq X plus and Oxford Nanopore P2 PromethION sequencing platforms to generate full-genome sequence data with phylogenetic and genotype-to-phenotype analysis; a $633.7 thousand firm fixed-price contract with FDA awarded September 2023 for development of a rabbit model to characterize antifungal drug resistance; and a $757.1 thousand purchase order contract awarded September 2023 from a civilian federal agency for research aimed at reducing resistance in detainees by enhancing empathy in interrogators. The University operates research facilities in Great Britain, United Kingdom, with NAICS and PSC coding split between biotechnology R&D (541714) and social-science research (541720), with health R&D services primary across the contract footprint.

Federal grant work spans multiple health and engineering disciplines. University Of Liverpool holds prime grants from the Air Force (thermoacoustic behavior of oxide-oxide ceramic plates and prior R&D in math and computer sciences), the Army Research Development and Engineering Command (machine learning for rotorcraft simulation models with uncertainty estimation, awarded July 2024 through June 2027), and the State Department's Bureau of European and Eurasian Affairs (international slavery education outreach, concluded June 2024). The university serves as sub-recipient on multi-institutional research grants anchored by Johns Hopkins University (long-acting antiretroviral formulations and tuberculosis prevention), La Jolla Institute for Immunology (tumor immunology and vaccination studies with Prof. Ottensmeier leading sample collection and clinical oversight across five sub-awards), University of Maryland Baltimore (HIV-exposed and uninfected infant neurocognitive development in Malawi, multi-award subawards), North Carolina State University (plasma-enhanced catalyst development for CO2-to-gasoline conversion, awarded February 2025), Yale University (rotavirus vaccine impact modeling in Malawi with field-site surveillance data collection), University of Pittsburgh (pediatric scleroderma multi-omic characterization), and Ann & Robert H. Lurie Children's Hospital (pediatric orthopedic trial steering committee participation).

Customer concentration sits with health and defense research agencies. The Department of Health and Human Services accounts for the largest combined potential value through three FDA contracts ($9.8 million) and eleven awards from the National Institute of Allergy and Infectious Diseases. The National Institute of Child Health and Human Development has placed six awards. The Department of the Air Force and Department of the Army Research Development and Engineering Command each account for six and five awards respectively. The Department of Justice Federal Bureau of Investigation Headquarters Division holds three awards ($979 thousand combined potential value). Eighteen distinct federal agencies have funded University Of Liverpool work across the source window. Activity grew from two awards in 2022 to twelve in 2024, with eight in 2025 and two in 2026 year to date. Three awards carry ultimate completion dates in the next twenty-four months with combined potential value of $350 thousand.